Publications by authors named "Colin Lindsay"

Claim this Profile
C
Clinical characteristics, healthcare resource use, and survival outcomes among patients with advanced NSCLC tested for KRAS mutations in France, the United Kingdom, and Switzerland.
Marie Wislez, Andromachi Giannopoulou, Isabelle Borget, Colin Lindsay, Sacha I Rothschild

J Med Econ· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Actionable Genomic Alterations in Large Cell Neuroendocrine Carcinoma: A European Case Series of Patients Treated With a Small Molecule Inhibitor.
Frank W J Heijboer, Marta Brambilla, Mario Occhipinti, Daniele Lorenzini, Wieneke A Buikhuisen, Colin R Lindsay

JCO Precis Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial.
Anne-Marie C Dingemans, Konstantinos Syrigos, Lorenzo Livi, Astrid Paulus, Sang-We Kim, Colin R Lindsay

Lung Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging Role of Targeted Therapies Combined With Radiotherapy in Inoperable Stages I to III NSCLC: A Review From the IASLC ART Subcommittee.
Sarah Bowen Jones, Clara Chan, Andrea R Filippi, Ken Harada, Alexander V Louie, Colin R Lindsay

J Thorac Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular determinants of sotorasib clinical efficacy in KRAS-mutated non-small-cell lung cancer.
Ferdinandos Skoulidis, Bob T Li, Adrianus Johannes de Langen, David S Hong, Herve Lena, Colin R Lindsay

Nat Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence and breakdown of driver mutations in a large UK non-small cell lung cancer cohort.
Isabella Caroline Chiara Niesner, Kevin Jon Balbi, Benjamin Poskitt, Carolina Gemma, Josep Linares, Colin R Lindsay

J Clin Pathol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary.
Adrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, Anne-Marie C Dingemans, Giannis Mountzios, Colin R Lindsay

Future Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Should Radiation Dose Be Personalized in Patients With Localized NSCLC and Actionable Genetic Alterations? Insight From a Multicenter Real-World Study.
Salman Ashraf, Madeha Khan, Nada Naguib, Robert Rulach, Katharine Welsh, Colin R Lindsay

JTO Clin Res Rep· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reconceptualising labour utilisation and underutilisation with new 'full-time equivalent' employment and unemployment rates.
Donald Houston, Colin Lindsay

J Labour Mark Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line osimertinib compared to earlier generation TKIs in advanced EGFR-mutant NSCLC: A real-world survival analysis.
Igor Gomez-Randulfe, Lauren A Scanlon, Mathew Carter, Laura Moliner, Emine Cil, Colin R Lindsay

Lung Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer.
Ferdinandos Skoulidis, Bob T Li, Maximilian Hochmair, Ramaswamy Govindan, Mark Vincent, Colin Lindsay

Oncologist· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma.
Loic Verlingue, Antoine Italiano, Hans Prenen, Eva Maria Guerra Alia, Diego Tosi, Colin R Lindsay

EBioMedicine· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer.
Hans Prenen, Sanjeev Deva, Bhumsuk Keam, Colin R Lindsay, Iwona Lugowska

Clin Cancer Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Service Evaluation of MyChristie-MyHealth, an Electronic Patient-Reported Outcome Measure Integrated Into Clinical Cancer Care.
Lee A Shipman, James Price, Danya Abdulwahid, Neil Bayman, Fiona Blackhall, Colin Lindsay

JCO Clin Cancer Inform· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion.
Mihaela Aldea, Arianna Marinello, Michael Duruisseaux, Wael Zrafi, Nicole Conci, Colin R Lindsay

J Thorac Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient and clinician-reported experiences of using electronic patient reported outcome measures (ePROMs) as part of routine cancer care.
Amelia Payne, Ashley Horne, Neil Bayman, Fiona Blackhall, Layla Bostock, Colin Lindsay

J Patient Rep Outcomes· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolution of non-small cell lung cancer metastases in TRACERx.
Maise Al Bakir, Ariana Huebner, Carlos Martínez-Ruiz, Kristiana Grigoriadis, Thomas B K Watkins, Colin R Lindsay

Nature· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Experience With the Routine Use of Electronic Patient-Reported Outcome Measures for Patients With Lung Cancer.
Cathryn Crockett, James Price, Mai Pham, Danya Abdulwahid, Neil Bayman, Colin Lindsay

JCO Clin Cancer Inform· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS mutation: a randomised, open-label, phase 3 trial.
Adrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, Anne-Marie C Dingemans, Giannis Mountzios, Colin R Lindsay

Lancet· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index.
Ana Ortega-Franco, Clare Hodgson, Haseem Raja, Mathew Carter, Colin Lindsay

Target Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
More to the RAS Story: KRAS Inhibition, Resistance Mechanisms, and Moving Beyond KRAS.
Caressa D Lietman, Melissa L Johnson, Frank McCormick, Colin R Lindsay

Am Soc Clin Oncol Educ Book· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma.
Colin R Lindsay, Marina C Garassino, Ernest Nadal, Katarina Öhrling, Matthias Scheffler

Lung Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists.
Colin R Lindsay, Emily C Shaw, David A Moore, Doris Rassl, Mariam Jamal-Hanjani

Br J Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of ROS1 by immunohistochemistry against fluorescent in situ hybridisation on cytology and small biopsy samples in a large teaching hospital.
Nadira Narine, Andrew Wallace, Jonathan Dore, Simon O'Leary-Jackson, Haider Al Najjar, Colin Lindsay

Cytopathology· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer.
Victoria Foy, Colin R Lindsay, Alexandra Carmel, Fabiola Fernandez-Gutierrez, Matthew G Krebs

Transl Lung Cancer Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis